Cysteine cathepsins and their potential in clinical therapy and biomarker discovery

Proteomics - Clinical Applications

Volumn 8, Issue 5-6, 2014, Pages 416-426

  Fonović, Marko ^a,b   Turk, Boris ^a,b  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b Centre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins   (Slovenia)

Author keywords

Biomarker; Cancer; Cathepsin; Cysteine protease; Proteolysis

Indexed keywords

BALICATIB; BIOLOGICAL MARKER; CATHEPSIN; CATHEPSIN B; CATHEPSIN H; CATHEPSIN K; CATHEPSIN K INHIBITOR; CATHEPSIN L; CATHEPSIN S; CATHEPSIN S INHIBITOR; CATHEPSIN X; CRA 028129; CYSTEINE CATHEPSIN; LOSARTAN; MATRIX METALLOPROTEINASE; MIV 711; ODANACATIB; ONO 5334; RELACATIB; RWJ 445380; UNCLASSIFIED DRUG; VBY 036; VBY 891; CYSTEINE;

ATHEROSCLEROSIS; BONE METASTASIS; CELLULAR DISTRIBUTION; DISEASE MARKER; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; OSTEOARTHRITIS; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; DISEASES; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; PROTEIN TRANSPORT;

ANIMALS; BIOLOGICAL MARKERS; CATHEPSINS; CYSTEINE; DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN TRANSPORT;

EID: 84902081517     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201300085     Document Type: Review

References (126)

1. Turk, B., Turk, D., Turk, V., Protease signalling: the cutting edge. EMBO J. 2012, 31, 1630-1643.
2. Turk, B., Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 2006, 5, 785-799.
3. Drag, M., Salvesen, G. S., Emerging principles in protease-based drug discovery. Nat. Rev. Drug Discov. 2010, 9, 690-701.
4. Overall, C. M., López-Otín, C., Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2002, 2, 657-672.
5. Coussens, L. M., Fingleton, B., Matrisian, L. M., Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295, 2387-2392.
6. Rawlings, N. D., Barrett, A. J., Bateman, A., MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 2012, 40, D343-D350.
7. Turk, D., Guncar, G., Podobnik, M., Turk, B., Revised definition of substrate binding sites of papain-like cysteine proteases. Biol. Chem. 1998, 379, 137-147.
8. Turk, V., Stoka, V., Vasiljeva, O., Renko, M. et al., Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim. Biophys. Acta 2012, 1824, 68-88.
9. Saftig, P., Klumperman, J., Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat. Rev. Mol. Cell Biol. 2009, 10, 623-635.
10. Goulet, B., Baruch, A., Moon, N. S., Poirier, M. et al., A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol. Cell 2004, 14, 207-219.
11. Duncan, E. M., Muratore-Schroeder, T. L., Cook, R. G., Garcia, B. A. et al., Cathepsin L proteolytically processes histone H3 during mouse embryonic stem cell differentiation. Cell 2008, 135, 284-294.
12. Santos-Rosa, H., Kirmizis, A., Nelson, C., Bartke, T. et al., Histone H3 tail clipping regulates gene expression. Nat. Struct. Mol. Biol. 2009, 16, 17-22.
13. Adams-Cioaba, M. A., Krupa, J. C., Xu, C., Mort, J. S., Min, J., Structural basis for the recognition and cleavage of histone H3 by cathepsin L. Nat. Commun. 2011, 2, 197.
14. Ceru, S., Konjar, S., Maher, K., Repnik, U. et al., Stefin B interacts with histones and cathepsin L in the nucleus. J. Biol. Chem. 2010, 285, 10078-10086.
15. Maubach, G., Lim, M. C., Zhuo, L., Nuclear cathepsin F regulates activation markers in rat hepatic stellate cells. Mol. Biol. Cell 2008, 19, 4238-4248.
16. Tedelind, S., Poliakova, K., Valeta, A., Hunegnaw, R. et al., Nuclear cysteine cathepsin variants in thyroid carcinoma cells. Biol. Chem. 2010, 391, 923-935.
17. Gocheva, V., Joyce, J. A., Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007, 6, 60-64.
18. Rozhin, J., Sameni, M., Ziegler, G., Sloane, B. F., Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res. 1994, 54, 6517-6525.
19. Cavallo-Medved, D., Dosescu, J., Linebaugh, B. E., Sameni, M. et al., Mutant K-ras regulates cathepsin B localization on the surface of human colorectal carcinoma cells. Neoplasia 2003, 5, 507-519.
20. Cheng, X. W., Kuzuya, M., Nakamura, K., Di, Q. et al., Localization of cysteine protease, cathepsin S, to the surface of vascular smooth muscle cells by association with integrin alphanubeta3. Am J. Pathol. 2006, 168, 685-694.
21. Obermajer, N., Repnik, U., Jevnikar, Z., Turk, B. et al., Cysteine protease cathepsin X modulates immune response via activation of beta2 integrins. Immunology 2008, 124, 76-88.
22. Drake, F. H., Dodds, R. A., James, I. E., Connor, J. R. et al., Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 1996, 271, 12511-12516.
23. Rieman, D. J., McClung, H. A., Dodds, R. A., Hwang, S. M. et al., Biosynthesis and processing of cathepsin K in cultured human osteoclasts. Bone 2001, 28, 282-289.
24. Friedrichs, B., Tepel, C., Reinheckel, T., Deussing, J. et al., Thyroid functions of mouse cathepsins B, K, and L. J. Clin. Invest. 2003, 111, 1733-1745.
25. Büth, H., Wolters, B., Hartwig, B., Meier-Bornheim, R. et al., HaCaT keratinocytes secrete lysosomal cysteine proteinases during migration. Eur. J. Cell Biol. 2004, 83, 781-795.
26. Turk, B., Turk, D., Salvesen, G. S., Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr. Pharm. Des. 2002, 8, 1623-1637.
27. Vasiljeva, O., Reinheckel, T., Peters, C., Turk, D. et al., Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des. 2007, 13, 387-403.
28. Reiser, J., Adair, B., Reinheckel, T., Specialized roles for cysteine cathepsins in health and disease. J. Clin. Invest. 2010, 120, 3421-3431.
29. Brömme, D., Okamoto, K., Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol. Chem. Hoppe. Seyler. 1995, 376, 379-384.
30. Kafienah, W., Brömme, D., Buttle, D. J., Croucher, L. J., Hollander, A. P., Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. Biochem. J. 1998, 331, 727-732.
31. Votta, B. J., Levy, M. A., Badger, A., Bradbeer, J. et al., Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J. Bone Miner. Res. 1997, 12, 1396-1406.
32. Inui, T., Ishibashi, O., Inaoka, T., Origane, Y. et al., Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J. Biol. Chem. 1997, 272, 8109-8112.
33. Saftig, P., Hunziker, E., Wehmeyer, O., Jones, S. et al., Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA 1998, 95, 13453-13458.
34. Gelb, B. D., Shi, G. P., Chapman, H. A., Desnick, R. J., Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996, 273, 1236-1238.
35. Das, S., Crockett, J. C., Osteoporosis-a current view of pharmacological prevention and treatment. Drug Des. Devel. Ther. 2013, 7, 435-448.
36. Hardingham, T. E., Fosang, A. J., Proteoglycans: many forms and many functions. FASEB J. 1992, 6, 861-870.
37. Felson, D. T., Neogi, T., Osteoarthritis: is it a disease of cartilage or bone? Arthritis Rheum. 2004, 50, 341-344.
38. Murphy, G., Nagase, H., Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat. Clin. Pract. Rheumatol. 2008, 4, 128-135.
39. Wilkins, R. J., Hall, A. C., Control of matrix synthesis in isolated bovine chondrocytes by extracellular and intracellular pH. J. Cell Physiol. 1995, 164, 474-481.
40. Konttinen, Y. T., Mandelin, J., Li, T. F., Salo, J. et al., Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum. 2002, 46, 953-960.
41. Goldring, S. R., Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology 2003, 42(Suppl 2), ii11-ii6.
42. Lenarčič, B., Gabrijelčič, D., Rozman, B., Drobnič-Košorok, M., Turk, V., Human cathepsin B and cysteine-proteinase inhibitors (CPIs) in inflamatory and metabolic join diseases. Biol. Chem. Hoppe Seyler 1988, 369, 257-261.
43. Gabrijelcic, D., Annan-Prah, A., Rodic, B., Rozman, B. et al., Determination of cathepsins B and H in sera and synovial fluids of patients with different joint diseases. J. Clin. Chem. Clin. Biochem. 1990, 28, 149-153.
44. Lemaire, R., Huet, G., Zerimech, F., Grard, G. et al., Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells. Br. J. Rheumatol. 1997, 36, 735-743.
45. Hansen, T., Petrow, P. K., Gaumann, A., Keyzser, G. M. et al., Cathepsin B and its endogenous inhibitor cystetin C in rheumatoid arthritis synovium. J. Rheumatol. 2000, 27, 859-865.
46. Požgan, U., Caglič, D., Rozman, B., Nagase, H. et al., Expression and activity profiling of selected cysteine proteases and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol. Chem. 2010, 391, 571-579.
47. Baici, A., Lang, A., Horler, D., Kissling, R., Merlin, C., Cathepsin B in osteoarthritis: cytochemical and histochemical analysis of human femoral head cartilage. Ann. Rheum. Dis. 1995, 54, 289-297.
48. Baici, A., Horler, D., Lang, A., Merlin, C., Kissling, R., Cathepsin B in osteoarthritis: zonal variation of enzyme activity in human femoral head cartilage. Ann. Rheum. Dis. 1995, 54, 281-288.
49. Lai, W. F., Chang, C. H., Tang, Y., Bronson, R., Tung, C. H., Early diagnosis of osteoarthritis using cathepsin B sensitive near-infrared fluorescent probes. Osteoarthr. Cartil. 2004, 12, 239-244.
50. Hou, W. S., Li, W., Keyszer, G., Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum. 2002, 46, 663-674.
51. Hou, W. S., Li, Z., Gordon, R. E., Chan, K. et al., Cathepsin K is a critical protease in synovial fibroblast mediated collagen degradation. Am J Pathol 2001, 159, 2167-2177.
52. Hou, W. S., Li, Z., Buttner, F. H., Bartnik, E., Bromme, D., Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation. Biol. Chem. 2003, 384, 891-897.
53. Cheng, X. W., Shi, G. P., Kuzuya, M., Sasaki, T. et al., Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation 2012, 125, 1551-1562.
54. Cheng, X. W., Obata, K., Kuzuya, M., Izawa, H. et al., Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertension heart failure. Hypertension 2006, 48, 979-987.
55. Stypmann, J., Glaser, K., Roth, W., Tobin, D. J. et al., Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc. Natl. Acad. Sci. USA 2002, 99, 6234-6239.
56. Petermann, I., Mayer, C., Stypmann, J., Biniossek, M. L. et al., Lysosomal, cytosceletal and metabolic alterations in cardiomyopathy of cathepsin L knockout mice. FASEB J. 2006, 20, 1266-1268.
57. Tang, Q., Cai, J., Shen, D., Bian, Z. et al., Lysosomal cysteine peptidase cathepsin L protects against cardiac hyperthrophy through blocking AKT/GSK3beta signaling. J. Mol. Med. 2006, 87, 249-260.
58. Urbich, C., Heeschen, C., Aicher, A., Sasaki, K. et al., Cathepsin L is required for endothelial progenitor cell induced neovascularisation. Nat. Med. 2005, 11, 206-213.
59. Sun, M, Chen, M., Liu, Y., Fukuoka, M. et al., Cathepsin L contributes to cardiac repair and remodeling post-infarction. Cardiovasc. Res. 2010, 89, 374-383.
60. Sun, M., Chen, M., Liu, Y., Fukuoka, M. et al., Cathepsin-L contributes to cardiac repair and remodelling post-infarction. Cardiovasc. Res. 2011, 89, 374-383.
61. Helske, S., Syvaranta, S., Lindstedt, K. A., Lappalainen, J. et al., Increased expression of elastolytic cathepsins S, K and V and their inhibitor cystatin C in stenotic aortic valves. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 1791-1798.
62. Balachandran, K., Sucosky, P., Jo, H., Yoganathan, A. P., Elevated cyclic stretch alters matrix remodeling in aortic valve cusps: implications for degenerative aortic valve disease. Am. J. Physiol. Heart Circ. Physiol. 2009, 296, H756-H764.
63. Balachandran, K., Sucosky, P., Jo, H., Yoganathan, A. P., Elevated cyclic stretch induces aortic valve calcification in a bone morphogenic protein dependant manner. Am. J. Pathol. 2010, 177, 49-57.
64. Aikawa, E., Aikawa, M., Libby, P., Figueiredo, J. L. et al., Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation 2009, 119, 1785-1794.
65. Sukhova, G. K., Shi, G. P., Simon, D. I., Chapman, H. A., Libby, P., Expression of elastinolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J. Clin. Invest. 1998, 102, 576-583.
66. Jormsjo, S., Wuttge, D. M., Sirsjo, A., Whatling, C. et al., Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apolipoprotein E-defficient mice. Am. J. Pathol. 2002, 161, 939-946.
67. Reddy, V. Y., Zhang, Q. Y., Weiss, S. J., Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc. Natl. Acad Sci. USA 1995, 92, 3849-3853.
68. Rodgers, K. J., Watkins, D. J., Miller, A. L., Chan, P. Y. et al., Destabilizing role of cathepsin S in murine atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 851-856.
69. Lutgens, E., Lutgens, S. P., Faber, B. C., Heeneman, S. et al., Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 2006, 113, 98-107.
70. Shimizu, K., Mitchell, R. N., Libby, P., Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 987-994.
71. Shi, G. P., Sukhova, G. K., Grubb, A., Ducharme, A. et al., Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J. Clin. Invest. 1999, 104, 1191-1197.
72. Liu, J., Sukhova, G. K., Yang, J. T., Sun, J. et al., Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis 2006, 184, 302-311.
73. Aoki, T., Kataoka, H., Ishibashi, R., Nozaki, K., Hashimoto, N., Cathepsin B, K, and S are expressed in cerebral aneurysms and promote the progression of cerebral aneurysms. Stroke 2008, 39, 2603-2610.
74. Cheng, X. W., Murohara, T., Kuzuya, M., Izawa, H. et al., Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am. J. Pathol. 2008, 173, 358-369.
75. Samokhin, A. O., Lythgo, P. A., Gauthier, J. Y., Percival, M. D., Brömme, D., Pharmacological inhibition of cathepsin S decreases atherosclerotic lesions in Apoe-/- mice. J. Cardiovasc. Pharmacol. 2010, 56, 98-105.
76. Suganuma, E., Babaev, V. R., Motojima, M., Zuo, Y. et al., Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques. J. Am. Soc. Nephrol. 2007, 18, 2311-2319.
77. Sloane, B. F., Dunn, J. R., Honn, K. V., Lysosomal cathepsin B: correlation with metastatic potential. Science 1981, 212, 1151-1153.
78. Berdowska, I., Cysteine proteases as disease markers. Clin. Chim. Acta 2004, 342, 41-69.
79. Mohamed, M. M., Sloane, B. F., Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6, 764-775.
80. Joyce, J. A., Baruch, A., Chehade, K., Meyer-Morse, N. et al., Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004, 5, 443-453.
81. Mikhaylov, G., Mikac, U., Magaeva, A. A., Itin, V. I. et al., Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat. Nanotechnol. 2011, 6, 594-602.
82. Vasiljeva, O., Papazoglou, A., Krüger, A., Brodoefel, H. et al., Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 2006, 66, 5242-5250.
83. Vasiljeva, O., Korovin, M., Gajda, M., Brodoefel, H. et al., Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene 2008, 27, 4191-4199.
84. Gocheva, V., Zeng, W., Ke, D., Klimstra, D. et al., Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006, 20, 543-556.
85. Sevenich, L., Schurigt, U., Sachse, K., Gajda, M. et al., Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc. Natl. Acad. Sci. USA 2010, 107, 2497-2502.
86. Vasiljeva, O., Turk, B., Dual contrasting roles of cysteine cathepsins in cancer progression: apoptosis versus tumour invasion. Biochimie 2008, 90, 380-386.
87. Stubbs, M., McSheehy, P. M., Griffiths, J. R., Bashford, C. L., Causes and consequences of tumour acidity and implications for treatment. Mol. Med. Today 2000, 6, 15-9.
88. Mason, S. D., Joyce, J. A., Proteolytic networks in cancer. Trends Cell Biol. 2011, 21, 228-237.
89. Hashimoto, Y., Kondo, C., Kojima, T., Nagata, H. et al., Significance of 32-kDa cathepsin L secreted from cancer cells. Cancer Biother. Radiopharm. 2006, 21, 217-224.
90. Rousselet, N., Mills, L., Jean, D., Tellez, C. et al., Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res. 2004, 64, 146-151.
91. Waghray, A., Keppler, D., Sloane, B. F., Schuger, L., Chen, Y. Q., Analysis of a truncated form of cathepsin H in human prostate tumor cells. J. Biol. Chem. 2002, 277, 11533-11538.
92. Flannery, T., Gibson, D., Mirakhur, M., McQuaid, S. et al., The clinical significance of cathepsin S expression in human astrocytomas. Am. J. Pathol. 2003, 163, 175-182.
93. Kobayashi, H., Moniwa, N., Sugimura, M., Shinohara, H. et al., Increased cell-surface urokinase in advanced ovarian cancer. Jpn. J. Cancer Res. 1993, 84, 633-640.
94. Rao, J. S., Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer 2003, 3, 489-501.
95. Guinec, N., Dalet-Fumeron, V., Pagano, M., "In vitro" study of basement membrane degradation by the cysteine proteinases, cathepsins B, B-like and L. Digestion of collagen IV, laminin, fibronectin, and release of gelatinase activities from basement membrane fibronectin. Biol. Chem. Hoppe Seyler 1993, 374, 1135-1146.
96. Mai, J., Sameni, M., Mikkelsen, T., Sloane, B. F., Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol. Chem. 2002, 383, 1407-1413.
97. Jevnikar, Z., Rojnik, M., Jamnik, P., Doljak, B. et al., Cathepsin H mediates the processing of talin and regulates migration of prostate cancer cells. J. Biol. Chem. 2013, 288, 2201-2209.
98. Pečar Fonović, U., Jevnikar, Z., Rojnik, M., Doljak, B. et al., Profilin 1 as a target for cathepsin X activity in tumor cells. PLoS One 2013, 8, e53918.
99. Stoka, V., Turk, B., Schendel, S. L., Kim, T. H. et al., Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J. Biol. Chem. 2001, 276, 3149-3157.
100. Shree, T., Olson, O. C., Elie, B. T., Kester, J. C. et al., Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011, 25, 2465-2479.
101. Palermo, C., Joyce, J. A., Cysteine cathepsin proteases as pharmacological targets in cancer. Trends. Pharmacol. Sci. 2008, 29, 22-28.
102. Lah, T. T., Kos, J., Blejec, A., Frkovic-Georgio, S. et al., The expression of lysosomal proteinases and their inhibitors in breast cancer: possible relationship to prognosis of the disease. Pathol. Oncol. Res. 1997, 3, 89-99.
103. Foekens, J. A., Kos, J., Peters, H. A., Krasovec, M. et al., Prognostic significance of cathepsins B and L in primary human breast cancer. J. Clin. Oncol. 1998, 16, 1013-1021.
104. Nouh, M. A., Mohamed, M. M., El-Shinawi, M., Shaalan, M. A. et al., Cathepsin B: a potential prognostic marker for inflammatory breast cancer. J. Transl. Med. 2011, 9, 1.
105. Kos, J., Werle, B., Lah, T., Brunner, N., Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int. J. Biol. Markers 2000, 15, 84-89.
106. Zhang, W., Yang, H. C., Wang, Q., Yang, Z. J. et al., Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis. Anticancer Res. 2011, 31, 3423-3428.
107. Kos, J., Sekirnik, A., Kopitar, G., Cimerman, N. et al., Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis. Br. J. Cancer 2001, 85, 1193-1200.
108. Jain, M., Bakhshi, S., Shukla, A. A., Chauhan, S. S., Cathepsins B and L in peripheral blood mononuclear cells of pediatric acute myeloid leukemia: potential poor prognostic markers. Ann. Hematol. 2010, 89, 1223-1232.
109. Schweiger, A., Christensen, I. J., Nielsen, H. J., Sørensen, S. et al., Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer. Int. J. Biol. Markers 2004, 19, 289-294.
110. Vizin, T., Christensen, I. J., Nielsen, H. J., Kos, J., Cathepsin X in serum from patients with colorectal cancer: relation to prognosis. Radiol. Oncol. 2012, 46, 207-212.
111. Liu, J., Ma, L., Yang, J., Ren, A. et al., Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis 2006, 186, 411-419.
112. Liu, Y., Li, X., Peng, D., Tan, Z. et al., Usefulness of serum cathepsin L as an independent biomarker in patients with coronary heart disease. Am. J. Cardiol. 2009, 103, 476-481.
113. Alehagen, U., Dahlström, U., Lindahl, T. L., Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur. J. Heart Fail. 2009, 11, 354-360.
114. Chen, J., Xi, J., Tian, Y., Bova, G. S., Zhang, H., Identification, prioritization, and evaluation of glycoproteins for aggressive prostate cancer using quantitative glycoproteomics and antibody-based assays on tissue specimens. Proteomics 2013, 13, 2268-2277.
115. Fonović, M., Bogyo, M., Activity based probes for proteases: applications to biomarker discovery, molecular imaging and drug screening. Curr. Pharm. Des. 2007, 13, 253-261.
116. Serim, S., Haedke, U., Verhelst, S. H., Activity-based probes for the study of proteases: recent advances and developments. Chem. Med. Chem. 2012, 7, 1146-1159.
117. Watzke, A., Kosec, G., Kindermann, M., Jeske, V. et al., Selective activity-based probes for cysteine cathepsins. Angew Chem. Int. Ed. Engl. 2008, 47, 406-409.
118. Paulick, M. G., Bogyo, M., Application of activity-based probes to the study of enzymes involved in cancer progression. Curr. Opin. Genet. Dev. 2008, 18, 97-106.
119. Caglič, D., Globisch, A., Kindermann, M., Lim, N. H. et al., Functional in vivo imaging of cysteine cathepsin activity in murine model of inflammation. Bioorg. Med. Chem. 2011, 19, 1055-1061.
120. Schilling, O., Overall, C. M., Proteomic discovery of protease substrates. Curr. Opin. Chem. Biol. 2007, 11, 36-45.
121. Findeisen, P., Neumaier, M., Functional protease profiling for diagnosis of malignant disease. Proteomics Clin. Appl. 2012, 6, 60-78.
122. Van Damme, P., Martens, L., Van Damme, J., Hugelier, K. et al., Caspase-specific and nonspecific in vivo protein processing during Fas-induced apoptosis. Nat. Methods 2005, 2, 771-777.
123. Overall, C. M., Blobel, C. P., In search of partners: linking extracellular proteases to substrates. Nat. Rev. Mol. Cell Biol. 2007, 8, 245-257.
124. Gevaert, K., Goethals, M., Martens, L., Van Damme, J. et al., Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat. Biotechnol. 2003, 21, 566-569.
125. Biniossek, M. L., Nägler, D. K., Becker-Pauly, C., Schilling, O., Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. J. Proteome Res. 2011, 10, 5363-5373.
126. Tholen, S., Biniossek, M. L., Gansz, M., Ahrens, T. D. et al., Double deficiency of cathepsins B and L results in massive secretome alterations and suggests a degradative cathepsin-MMP axis. Cell Mol. Life Sci. 2013, 71, 899-916.